Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN: Trastuzumab in a Neoadjuvant Regimen for HER2-positive Breast Cancer
2008-000987-18Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic complete response at surgery. Started Mar 2008; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000987-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000987-18.